Exact Sciences Corporation $EXAS Shares Sold by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. lowered its position in Exact Sciences Corporation (NASDAQ:EXAS) by 66.7% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 49,491 shares of the medical research company’s stock after selling 99,138 shares during the period. Robeco Institutional Asset Management B.V.’s holdings in Exact Sciences were worth $2,630,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Larson Financial Group LLC raised its position in shares of Exact Sciences by 2,804.8% in the first quarter. Larson Financial Group LLC now owns 610 shares of the medical research company’s stock worth $26,000 after acquiring an additional 589 shares during the period. National Pension Service increased its stake in shares of Exact Sciences by 75.1% during the first quarter. National Pension Service now owns 681 shares of the medical research company’s stock worth $29,000 after purchasing an additional 292 shares in the last quarter. SVB Wealth LLC purchased a new stake in shares of Exact Sciences during the first quarter worth about $30,000. Banque Cantonale Vaudoise purchased a new stake in shares of Exact Sciences during the first quarter worth about $34,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Exact Sciences during the first quarter worth about $34,000. Institutional investors and hedge funds own 88.82% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently commented on EXAS. Craig Hallum boosted their target price on shares of Exact Sciences from $65.00 to $85.00 and gave the stock a “buy” rating in a research note on Thursday, September 11th. Evercore ISI boosted their target price on shares of Exact Sciences from $64.00 to $68.00 and gave the stock an “outperform” rating in a research note on Tuesday. Wells Fargo & Company set a $68.00 target price on shares of Exact Sciences in a research note on Wednesday, October 1st. BTIG Research dropped their price objective on shares of Exact Sciences from $65.00 to $60.00 and set a “buy” rating for the company in a research note on Tuesday, August 12th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Exact Sciences in a research note on Saturday, September 27th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $68.71.

Insider Transactions at Exact Sciences

In other Exact Sciences news, Director James Edward Doyle sold 1,485 shares of the stock in a transaction that occurred on Wednesday, August 13th. The shares were sold at an average price of $42.02, for a total transaction of $62,399.70. Following the sale, the director directly owned 59,962 shares in the company, valued at $2,519,603.24. This represents a 2.42% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 1.20% of the stock is currently owned by company insiders.

Exact Sciences Stock Performance

Shares of EXAS stock opened at $57.75 on Wednesday. The firm’s 50 day moving average price is $49.97 and its 200-day moving average price is $50.27. The company has a debt-to-equity ratio of 0.94, a quick ratio of 2.56 and a current ratio of 2.89. Exact Sciences Corporation has a one year low of $38.81 and a one year high of $72.83. The firm has a market cap of $10.93 billion, a P/E ratio of -10.64, a P/E/G ratio of 5.32 and a beta of 1.24.

Exact Sciences (NASDAQ:EXAS) last released its earnings results on Wednesday, August 6th. The medical research company reported $0.22 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.24. The company had revenue of $811.09 million for the quarter, compared to analyst estimates of $774.43 million. Exact Sciences had a negative net margin of 34.19% and a negative return on equity of 1.75%. The firm’s quarterly revenue was up 16.0% on a year-over-year basis. During the same period in the prior year, the business earned ($0.09) EPS. As a group, equities research analysts predict that Exact Sciences Corporation will post -0.58 EPS for the current year.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.